Crinetics Pharmaceuticals, Inc

Short Term Long Term Short Term Comparison Long Term Comparison
  • CRNX
  • 1d-2.04%
  • 1w-6.89%
  • 1m12.20%
  • 1y174.20%
ATH
  • ATH Price$48.03
  • ATH Date2024-04-11
  • % since ATH-9.06%
  • % to ATH9.96%
ATL
  • ATL Price$11.52
  • ATL Date2020-03-16
  • % from ATL279.17%
  • Last Low Price$43.68
  • Last Low Date2024-04-15
  • % From Last Low0%
IPO
  • IPO Price$19.25
  • % Current ROI USD226.91%
  • ATH Price$48.03
  • % ROI ATH 41,692.71%
[addtoany]

Graph takes few seconds to load...

[financial_chart symbol="CRNX"]

Key Data [addtoany]

Current price $43.68
Sector Healthcare
Industry Biotechnology
Today's High/Low $44.88/$43.44
Volume 540,666.00
Previous Close $44.59
52 Week High/Low $49.5799/$15.76
Market Cap 3,403,960,832.00
P/E Ratio 0
Forward P/E 1 Yr. $0.00
Earnings Per Share(EPS) $-3.54
Annualized Dividend $0
$43.68
[addtoany]

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors.
Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 biased agonist that has completed phase II clinical trial for the treatment of acromegaly, as well as completed phase 1 clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs).
The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist to treat congenital hyperinsulinism, which is in phase 1 clinical trial; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase 1 clinical trial for the treatment of Cushing’s and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was founded in 2008 and is headquartered in San Diego, California.

Annual Data | Millions of US $ except per share data 2019-12-312018-12-312017-12-312016-12-31
Cash on hand $118.39$163.88$14.19$12.15
Receivables $1.38$1.92$0.73$0.07
Inventory ----
Pre-Paid Expenses ----
Other Current Assets $2.48$0800000$0.10$0.04
Total Current Assets $123.34$166.68$15.17$12.37
Property, Plant, And Equipment $6.46$4.23$0.40$0.22
Long-Term Investments ----
Goodwill And Intangible Assets ----
Other Long-Term Assets $0.58$0.50$0.03$0.01
Total Long-Term Assets $7.04$4.73$0.43$0.23
Total Assets $130.38$171.42$15.60$12.60
Total Current Liabilities $8.34$7.93$0.90$0.89
Long Term Debt ---$0.16
Other Non-Current Liabilities $0.05$3.27$0.02$0.01
Total Long Term Liabilities $4.90$3.27$29.72$17.91
Total Liabilities $13.24$11.19$30.62$18.80
Common Stock Net $210.79$203.54$0100000$0400000
Retained Earnings (Accumulated Deficit) $-93.80$-43.38$-16.27$-7.11
Comprehensive Income ----
Other Share Holders Equity $0.15$0.06--
Share Holder Equity $117.14$160.23$-15.02$-6.20
Total Liabilities And Share Holders Equity ----